Publications: Prof Klaus Schmierer

Arun T, Petheram K, Tallantyre E, Ford H, Chataway J, Mac Dougall N, Doshi-Singh A, Englezou C et al. ( 2024 ) . Assessing the Landscape and Charting Paths: UK Neurology Trainees’ opinions on neuroinflammation subspecialty . Multiple Sclerosis and Related Disorders

Ammoscato F, Wafa M, Skonieczna J, Bestwick J, Monero R, Andrews M, De Trane S, Holden D et al. ( 2024 ) . Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells . Clinical Immunology vol. 269 ,

Thomson A, Horne R, Chapman C, Bharadia T, Burke P, Colwell E, Harrington M, Boskovic B et al. ( 2024 ) . Engaging a community to focus on upper limb function in people with multiple sclerosis: the ThinkHand campaign case study . Research Involvement and Engagement vol. 10 , ( 1 )

Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA, Pepper G, Schmierer K ( 2024 ) . Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified? . Multiple Sclerosis and Related Disorders vol. 87 ,

Nicholas R, Tallantyre EC, Witts J, Marrie RA, Craig EM, Knowles S, Pearson OR, Harding K et al. ( 2024 ) . Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales . Journal of Neurology Neurosurgery & Psychiatry vol. 95 , ( 11 ) 1032 - 1035 .

Schmierer K, Lassmann H ( 2024 ) . The shoulders we keep standing on: remembering Otto Marburg, a big brain in neurology and multiple sclerosis, at 150 . Acta Neuropathologica vol. 147 , ( 1 )

Ammoscato F, Skonieczna J, Bestwick J, Holden D, Aboulwafa M, Andrews M, Turner B, Marta M et al. ( 2024 ) . Prospective Longitudinal Study of Cladribine Tablets (CLADB Study) Demonstrates Sustained Reduction in Kappa Free Light Chains in Relapsing Multiple Sclerosis (RRMS) at 96 Weeks (P10-6.008) . Neurology vol. 102 , ( 17_supplement_1 )

Giovannoni G, Ford HL, Schmierer K, Middleton R, Stennett AM, Pomeroy I, Fisniku L, Scalfari A et al. ( 2024 ) . MS care: integrating advanced therapies and holistic management . Frontiers in Neurology vol. 14 ,

Baker D, Kang AS, Giovannoni G, Schmierer K ( 2023 ) . Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 82 ,

Hodgkinson S, Derfuss T, Sellebjerg F, Vermersch P, Barkhof F, Schmierer K, De Stefano N, Achiron A et al. ( 2023 ) . Investigation of Changes in Lymphocyte Subset Counts and their Relationship with MRI Outcomes in the Magnify-MS Study . Multiple Sclerosis and Related Disorders vol. 80 ,

Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, Giovannoni G, Gnanapavan S et al. ( 2023 ) . Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis . Therapeutic Advances in Neurological Disorders vol. 16 ,

Salavisa M, Mohamed B, Allen-Philbey K, Stennett AM, Campion T, Schmierer K ( 2023 ) . Parakinesia Brachialis Oscitans in a Patient With a First Manifestation of Multiple Sclerosis . Neurology Clinical Practice vol. 13 , ( 6 )

Dubuisson N, de Maere d'Aertrijcke O, Marta M, Gnanapavan S, Turner B, Baker D, Schmierer K, Giovannoni G et al. ( 2023 ) . Anaesthetic management of people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 80 ,

Seaton A, Baker D, Hedstrom AK, Alfredsson L, Schmierer K ( 2023 ) . Organic solvents and Multiple Sclerosis: the doubled risk dilemma . Occupational Medicine vol. 73 , ( 6 ) 300 - 303 .

Schmierer K ( 2023 ) . Honing in on magnetic resonance imaging predictors of multiple sclerosis pathology . Brain Pathology vol. 33 , ( 6 )

Lerede A, Rodgers J, Middleton RM, Hampshire A, Nicholas R, Coles A, Chataway J, Duddy M et al. ( 2023 ) . Patient-reported outcomes in multiple sclerosis: a prospective registry cohort study . Brain Communications vol. 5 , ( 4 )

Dobson R ( 2023 ) . Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination . Multiple Sclerosis Journal

Wiendl H, De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S et al. ( 2023 ) . Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study (S16.006) . Neurology . vol. 100 ,

De Stefano N, Achiron A, Barkhof F, Chan A, Derfuss T, Hodgkinson S, Leocani L, Montalban X et al. ( 2023 ) . Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study (P6-3.018) . Neurology . vol. 100 ,

Webb EJD, Meads D, Eskytė I, Ford HL, Bekker HL, Chataway J, Pepper G, Marti J et al. ( 2023 ) . Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices . The Patient - Patient-Centered Outcomes Research vol. 16 , ( 5 ) 457 - 471 .

De Stefano N, Achiron A, Barkhof F, Chan A, Derfuss T, Hodgkinson S, Leocani L, Montalban X et al. ( 2023 ) . Early onset of Action and Sustained Efficacy of MRI Outcomes during Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-Year MAGNIFY-MS Study . Multiple Sclerosis and Related Disorders vol. 71 ,

Schmierer K ( 2023 ) . A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets . Video Journal of Biomedicine

Wiendl H, De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S et al. ( 2023 ) . Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study . MULTIPLE SCLEROSIS JOURNAL . vol. 29 , 21 - 22 .

Schmierer K, Wiendl H, Oreja-Guevara C, Centonze D, Chudecka A, Roy S, Boschert U ( 2022 ) . A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets . Neurodegenerative Disease Management vol. 13 , ( 1 ) 15 - 21 .

Esposito G, Sima D, Smeets D, Schmierer K ( 2022 ) . EE257 Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK . Value in Health vol. 25 , ( 12 )

Baker D, Forte E, Pryce G, Kang AS, James LK, Giovannoni G, Schmierer K ( 2022 ) . The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination . Multiple Sclerosis and Related Disorders vol. 69 ,

Wiendl H, Schmierer K, Hodgkinson S, Derfuss T, Chan A, Sellebjerg F, Achiron A, Montalban X et al. ( 2022 ) . Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets . Neurology Neuroimmunology & Neuroinflammation vol. 10 , ( 1 )

Schmierer K, Redha I, Hammond V, Baker D, Barkhof F, Hooper R, Rashid W, Singh-Curry V et al. ( 2022 ) . 152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 93 ,

Schmierer K, Baker D, Nawaz T, Allen-Philbey K, Barkhof F, Chataway J, Hooper R, Mihaylova B et al. ( 2022 ) . 153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS) . Journal of Neurology Neurosurgery & Psychiatry . vol. 93 ,

Cauchi M, Willis M, Andrews A, Backx M, Brownlee W, Ford HL, Gran B, Jolles S et al. ( 2022 ) . Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline . Practical Neurology vol. 22 , ( 5 ) 344 - 357 .

K A-P, A S, T B, AC J, A M, S G, R D, G G et al. ( 2022 ) . Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 65 ,

de Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A et al. ( 2022 ) . Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis . Neurology Neuroimmunology & Neuroinflammation vol. 9 , ( 4 )

Topcu G, Smith L, Mhizha-Murira JR, Goulden N, Hoare Z, Drummond A, Fitzsimmons D, Evangelou N et al. ( 2022 ) . Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial . Pilot and Feasibility Studies vol. 8 , ( 1 )

Schmierer K, Wiendl H, Oreja-Guevara C, Centonze D, Chudecka A, Roy S, Boschert U ( 2022 ) . Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis . Multiple Sclerosis Journal vol. 28 , ( 13 ) 2151 - 2153 .

Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, Chance R, Evangelou N et al. ( 2022 ) . Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 64 ,

Lieberman DR, Mangat HK, Schmierer K ( 2022 ) . 028  Cladribine to halt deterioration in people with advanced multiple sclerosis (ChariotMS) . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a22.2 - a2a22 .

Schmierer K, Wolinsky JS, Brochet B, Hartung H-P, Naismith R, Koendgen H, Manfrini M, Sauter A et al. ( 2022 ) . 031  Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a23.1 - a2a23 .

Schmierer K, Bar-Or A, Bermel R, Weber MS, Hughes R, Lin C-J, Wang J-M, Craviero L et al. ( 2022 ) . 033  Ocrelizumab: serum Ig levels and serious infections . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a23.3 - a2a24 .

Schmierer K, Hauser SL, Kappos L, Montalban X, Craveiro L, Hughes R, Prajapati K, Koendgen H et al. ( 2022 ) . 034  Updated safety analysis of ocrelizumab in multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a24.1 - a2a24 .

Andrews M, Delaney M, Schmierer K, Dobson R, Marshall C ( 2022 ) . 076  What is the cost? An audit of investigations sent before and during lumbar puncture (LP) . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a124.2 - a1a124 .

Kuri A, Jacobs BM, Leddy S, Schmierer K, Turner B, Allen-Philbey K, Stennett A, Giovannoni G et al. ( 2022 ) . 091  Evaluation of remote assessments for multiple sclerosis in a real-world setting . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a129.1 - a1a129 .

Adegboyega G, Lobo R, Alsousa I, Salman R, Lobo S, Uppal E, Ali S, Schmierer K et al. ( 2022 ) . 170  Did the atraumatic lumbar puncture needle campaign have any effect? . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a62.1 - a6a62 .

Sousa I, Salman R, Lobo R, Adegboyega G, Lobo S, Uppal E, Ali S, Schmierer K et al. ( 2022 ) . 178  Atraumatic lumbar puncture campaign – effect on complications . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a64.2 - a6a64 .

Allen CM, Morgan P, Craner M, Tallantyre E, Schmierer K, Dineen R, Fitzsimmons D, DasNair R et al. ( 2022 ) . 222  DECISIve – DiagnosE using the Central veIn SIgn. A study comparing T2* MRI and lumbar puncture . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a77.2 - a7a77 .

Allen-Philbey K, Trane SD, Yildiz O, Adams A, Turner B, Marta M, Mathews J, Altmann D et al. ( 2022 ) . Personalised immunotherapy in active multiple sclerosis using injectable cladrib- ine: Follow-up of the BartsMS cohort . Journal of Neurology Neurosurgery & Psychiatry vol. 93 , ( 6 ) a2.3 - a2a2 .

Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R ( 2022 ) . Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals? . Clin Exp Immunol vol. 207 , ( 3 ) 263 - 271 .

Allen-Philbey K, Marta M, Gnanapavan S, Baker D, Schmierer K ( 2022 ) . Disease activity after cladribine immune reconstitution therapy: To repeat or to retreat? (P9-4.002) . Neurology vol. 98 , ( 18_supplement )

Yildiz O, Schroth J, Lombardi V, Pucino V, Bobeva Y, Yip PK, Schmierer K, Mauro C et al. ( 2022 ) . The Expression of Active CD11b Monocytes in Blood and Disease Progression in Amyotrophic Lateral Sclerosis . International Journal of Molecular Sciences vol. 23 , ( 6 )

McDowell AR, Petrova N, Carassiti D, Miquel ME, Thomas DL, Barker GJ, Schmierer K, Wood TC ( 2022 ) . High‐resolution quantitative MRI of multiple sclerosis spinal cord lesions . Magnetic Resonance in Medicine vol. 87 , ( 6 ) 2914 - 2921 .

Allen-Philbey K, Andrews M, Redha I, Papachatzaki M, Marta M, Gnanapavan S, Mathews J, Turner B et al. ( 2022 ) . CLADRIPLAS: Does cladribine Target CNS plasma cells and reduce neuro-axonal damage in people with MS? . MULTIPLE SCLEROSIS JOURNAL . vol. 28 , 769 - 770 .

Esposito G, Sima D, Smeets D, Schmierer K ( 2022 ) . COST-EFFECTIVENESS ANALYSIS OF AI-ASSISTED RADIOLOGICAL ASSESSMENT IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK . VALUE IN HEALTH . vol. 25 , S104 - S104 .

De Stefano N, Achiron A, Barkhof F, Chan A, Derfuss T, Hodgkinson S, Leocani L, Montalban X et al. ( 2022 ) . Early onset of action and sustained efficacy of MRI outcomes during cladribine tablets treatment in highly active relapsing multiple sclerosis: results of the 2-year MAGNIFY-MS study . MULTIPLE SCLEROSIS JOURNAL . vol. 28 , 629 - 631 .

Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2022 ) . Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study . MULTIPLE SCLEROSIS JOURNAL . vol. 28 , 33 - 34 .

Upcott M, Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, Chance R et al. ( 2022 ) . Humoral and T- cell response to multiple COVID-19 booster vaccinations in people with MS . MULTIPLE SCLEROSIS JOURNAL . vol. 28 , 365 - 366 .

Redha I, Lees M, Campbell D, Campion T, Malaspina A, Schmierer K ( 2022 ) . Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations – a rare but important differential diagnosis of cerebral vasculitis and demyelination . Neuroimmunology Reports vol. 2 ,

Baker D ( 2021 ) . CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis . Multiple Sclerosis and Related Disorders

Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X et al. ( 2021 ) . Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients . Therapeutic Advances in Neurological Disorders vol. 14 ,

Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2021 ) . Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study . Multiple Sclerosis and Related Disorders vol. 57 ,

Dobson R, Baker D, Kang A, Schmierer K, Giovannoni G ( 2021 ) . COVID-19 vaccine response in people with multiple sclerosis . Annals of Neurology

Rodgers J, Friede T, Vonberg FW, Constantinescu CS, Coles A, Chataway J, Duddy M, Emsley H et al. ( 2021 ) . The impact of smoking cessation on multiple sclerosis disease progression . Brain vol. 145 , ( 4 ) 1368 - 1378 .

Fernandes L, Allen CM, Williams T, Tallantyre E, Evangelou N, Chataway J, Ford HL, Abuown A et al. ( 2021 ) . The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK . Multiple Sclerosis and Related Disorders vol. 55 ,

Kuri A, Jacobs BM, Leddy S, Schmierer K, Turner B, Allen-Philbey K, Stennett A, Giovannoni G et al. ( 2021 ) . Evaluation of remote assessments for multiple sclerosis in an in-home setting . Multiple Sclerosis and Related Disorders vol. 54 ,

Dobson R, ALLEN-PHILBEY K, Giovannoni G, Baker D, Schmierer K ( 2021 ) . Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis . Multiple Sclerosis and Related Disorders

Schmierer K, Giovannoni G ( 2021 ) . MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary . Multiple Sclerosis Journal vol. 27 , ( 7 ) 1006 - 1007 .

Wiendl H, Schmierer K, Hodgkinson S, Derfuss T, Chan A, Sellebjerg F, Achiron A, Montalban X et al. ( 2021 ) . Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study (2235) . Neurology vol. 96 , ( 15_supplement )

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up (2528) . Neurology vol. 96 , ( 15_supplement )

Schmierer K, Lazure P, Oh J, Leist T, Murray S, Péloquin S ( 2021 ) . Identifying Gaps in Knowledge, Skills and Confidence among MS Specialists to Facilitate Improved MS Care (1732) . Neurology vol. 96 , ( 15_supplement )

De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A et al. ( 2021 ) . Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis (1921) . Neurology vol. 96 , ( 15_supplement )

Schmierer K, Sørensen PS, Baker D ( 2021 ) . Highly effective disease-modifying treatment as initial MS therapy . Current Opinion in Neurology vol. 34 , ( 3 ) 286 - 294 .

Péloquin S, Schmierer K, Leist TP, Oh J, Murray S, Lazure P ( 2021 ) . Challenges in multiple sclerosis care: Results from an international mixed-methods study . Multiple Sclerosis and Related Disorders vol. 50 ,

Stennett A, Allen-Philbey K, Begum T, Johnson A, Dobson R, Giovannoni G, Gnanapavan S, Marta M et al. ( 2021 ) . An evaluation of remote monitoring in people with MS during the COVID-19 pandemic . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 268 - 269 .

Wiendl H, Schmierer K, Hodgkinson S, Derfuss T, Chan A, Sellebjerg F, Achiron A, Montalban X et al. ( 2021 ) . Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study . NEUROLOGY . vol. 96 ,

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 90 - 91 .

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up . NEUROLOGY . vol. 96 ,

Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2021 ) . Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 514 - 515 .

Schmierer K, Lazure P, Oh J, Leist T, Murray S, Peloquin S ( 2021 ) . Identifying Gaps in Knowledge, Skills and Confidence among MS Specialists to Facilitate Improved MS Care . NEUROLOGY . vol. 96 ,

Peloquin S, Schmierer K, Oh J, Leist T, Murray S, Lazure P ( 2021 ) . Interprofessional collaboration and patient-provider communication challenges in MS care: a mixed-methods needs assessment . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 731 - 732 .

De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A et al. ( 2021 ) . Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis . NEUROLOGY . vol. 96 ,

Vickaryous N, Asardag AN, Chance R, Jones M, Bestwick J, Shah SN, George K, Schmierer K et al. ( 2021 ) . Seroconversion following vaccination against SARS-CoV-2 in people with MS: impact of disease modifying therapy . MULTIPLE SCLEROSIS JOURNAL vol. 27 , ( 2_SUPPL ) 775 - 776 .

Rodgers WJ, Friede T, Vonberg FW, Constantinescu CS, Coles A, Chataway J, Emsley H, Ford H et al. ( 2021 ) . The impact of smoking cessation on multiple sclerosis disease progression . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 41 - 42 .

Smets I, Holden D, Bianchi L, Ammoscato F, Turner B, Marta M, Schmierer K, Giovannoni G et al. ( 2021 ) . Treatment-Induced Reductions in Cerebrospinal Fluid Neurofilament Light Levels are Age-Dependent in Multiple Sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 27 - 28 .

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Up to 6 years follow-up of people with MS (n=250) receiving cladribine . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 546 - 547 .

Stamenova S, Redha I, Schmierer K, Garcia ME ( 2020 ) . FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) unmasked by withdrawal of immunosuppression for Crohn's disease? . Multiple Sclerosis and Related Disorders vol. 48 ,

Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung H-P, Arnold D et al. ( 2020 ) . Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial . The Lancet Neurology vol. 19 , ( 12 ) 988 - 997 .

Mateo-Casas M, Reyes S, De Trane S, Edwards F, Espasandin M, Anjorin G, Baker D, Schmierer K et al. ( 2020 ) . Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not? . eNeurologicalSci vol. 21 ,

Manzano A, Eskyté I, Ford HL, Pavitt SH, Potrata B, Schmierer K, Chataway J, Webb EJD et al. ( 2020 ) . Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 46 ,

Dobson R, Giovannoni G, Cuzick J ( 2020 ) . Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment . International Journal of Epidemiology

Schmierer K, Gnanapavan S, Giovannoni G, Ammoscato F, Holden D, Carrillo-Loza K, Christmas T, Bianchi L et al. ( 2020 ) . CSF neurofilament light chain testing as an aid to determine treatment strategies in MS . Neurology, Neuroimmunology and Neuroinflammation vol. 7 , ( 6 )

Reyes S, Smets I, Holden D, Carrillo-Loza K, Christmas T, Bianchi L, Ammoscato F, Turner B et al. ( 2020 ) . CSF neurofilament light chain testing as an aid to determine treatment strategies in MS . Neurology Neuroimmunology & Neuroinflammation vol. 7 , ( 6 )

Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G et al. ( 2020 ) . COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases . Clinical and Experimental Immunology vol. 202 , ( 2 ) 149 - 161 .

Petrova N, Nutma E, Carassiti D, Newman JR, Amor S, Altmann DR, Baker D, Schmierer K ( 2020 ) . Synaptic Loss in Multiple Sclerosis Spinal Cord . Annals of Neurology vol. 88 , ( 3 ) 619 - 625 .

Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, Mathews J, Lambourne J et al. ( 2020 ) . Protecting people with multiple sclerosis through vaccination . Practical Neurology

Webb EJD, Meads D, Eskytė I, Ford HL, Bekker HL, Chataway J, Pepper G, Marti J et al. ( 2020 ) . The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments . The Patient - Patient-Centered Outcomes Research vol. 13 , ( 5 ) 583 - 597 .

Iacobaeus E, Arrambide G, Amato MP, Derfuss T, Vukusic S, Hemmer B, Tintore M, Brundin L et al. ( 2020 ) . Aggressive multiple sclerosis (1): Towards a definition of the phenotype . Multiple Sclerosis Journal vol. 26 , ( 9 ) 1031 - 1044 .

Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, Brundin L, Tintore M et al. ( 2020 ) . Aggressive multiple sclerosis (2): Treatment . Multiple Sclerosis Journal vol. 26 , ( 9 ) 1045 - 1063 .

Allen-Philbey K, Middleton R, Tuite-Dalton K, Baker E, Stennett A, Albor C, Schmierer K ( 2020 ) . Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement? . Frontiers in Neurology vol. 11 ,

Saxena G, Moore JM, Jones M, Pryce G, Ali L, Leisegang GR, Vijay V, Loveless S et al. ( 2020 ) . Detecting and predicting neutralization of alemtuzumab responses in MS . Neurology Neuroimmunology & Neuroinflammation vol. 7 , ( 4 )

Baker D, Pryce G, James LK, Marta M, Schmierer K ( 2020 ) . The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis . Multiple Sclerosis and Related Disorders Article 102279 , 102279 - 102279 .

Amor S, Baker D, Khoury SJ, Schmierer K, Giovanonni G ( 2020 ) . SARS‐CoV‐2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad . Annals of Neurology vol. 87 , ( 6 ) 794 - 797 .

Manzano A, Eskytė I, Ford HL, Bekker HL, Potrata B, Chataway J, Schmierer K, Pepper G et al. ( 2020 ) . Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis . Patient Education and Counseling vol. 103 , ( 12 ) 2540 - 2547 .

Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G ( 2020 ) . The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic . Multiple Sclerosis and Related Disorders vol. 43 ,

Mateo-Casas M, Reyes S, O'Toole EA, De Trane S, Yildiz O, Allen-Philbey K, Mathews J, Baker D et al. ( 2020 ) . Severe skin reactions associated with cladribine in people with multiple sclerosis . Multiple Sclerosis and Related Disorders . vol. 43 ,

De Stefano N, Achiron A, Barkhof F, Chan A, Derfuss T, Hodgkinson S, Leocani L, Montalban X et al. ( 2020 ) . A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY-MS Baseline Analysis (1487) . Neurology . vol. 94 ,

Schmierer K, Baker D ( 2020 ) . B cells and multiple sclerosis spinal cord pathology . Brain Pathology vol. 30 , ( 4 ) 730 - 731 .

Schmierer K, Peniuta M, Oh J, Leist T, Lazure P, Peloquin S ( 2020 ) . Identifying Gaps in Knowledge, Skill and Confidence Among MS Specialists to Facilitate Appropriate Evolutions in MS Care (444) . Neurology vol. 94 , ( 15_supplement )

Ali L, SAXENA G, Jones M, Leisegang G, Gammon L, Gnanapavan S, Giovannoni G, Schmierer K et al. ( 2020 ) . A cell-based assay for the detection of neutralizing antibodies against alemtuzumab . BioTechniques: the journal of laboratory technology for bioresearch

Reyes S, Suarez S, Allen-Philbey K, Yildiz Ö, Mathews J, Anjorin G, Edwards F, Jain C et al. ( 2020 ) . Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 41 ,

Baker D, Ali L, SAXENA G, Pryce G, Jones M, Schmierer K, Giovannoni G, Gnanapavan S et al. ( 2020 ) . The irony of humanization: Alemtuzumab the first, but one of the most immunogenic, humanized monoclonal antibodies . Frontiers in Immunology vol. 11 , ( 124 )

Saxena GK, Theocharopoulos I, Aziz NT, Jones M, Gnanapavan S, Giovannoni G, Schmierer K, Garnett JA et al. ( 2020 ) . GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains . Scientific Reports vol. 10 , ( 1 ) Article 1860 ,

Baker D, Pryce G, James LK, Marta M, Schmierer K ( 2020 ) . The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis . Multiple Sclerosis and Related Disorders2020.01.09.20016774 - 2020.01.09.20016774 .

De Stefano N, Achiron A, Barkhof F, Chan A, Derfuss T, Hodgkinson S, Leocani L, Montalban X et al. ( 2020 ) . A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY-MS Baseline Analysis . NEUROLOGY . vol. 94 ,

Smets I, Reyes S, Carrillo-Loza K, Mateo-Casas M, Bianchi L, Holden D, Ammoscato F, Turner B et al. ( 2020 ) . CSF Neurofilament Light Chain for guiding individual treatment decisions in multiple sclerosis . EUROPEAN JOURNAL OF NEUROLOGY . vol. 27 , 475 - 476 .

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2020 ) . Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 522 - 523 .

Lieberman D, Mangat H, Allen-Philbey K, Baker D, Barkhof F, Chandran S, Chapman C, Chataway J et al. ( 2020 ) . Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS) . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 212 - 213 .

Schmierer K, Peniuta M, Oh J, Leist T, Lazure P, Peloquin S ( 2020 ) . Identifying Gaps in Knowledge, Skill and Confidence Among MS Specialists to Facilitate Appropriate Evolutions in MS Care . NEUROLOGY . vol. 94 ,

Schmierer K, Peniuta M, Oh J, Leist T, Lazure P, Peloquin S ( 2020 ) . Identifying gaps in knowledge, skills and confidence among ms specialists to facilitate improved ms care . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 638 - 639 .

De Stefano N, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A et al. ( 2020 ) . Reduction in cua mri lesions in the first 6 months of cladribine tablets treatment for highly active relapsing multiple sclerosis: magnify-ms study . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 303 - 303 .

Giovannoni G, Brex P, Dhiraj D, Fullarton J, Freddi M, Rodgers-Gray B, Schmierer K ( 2019 ) . Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme . Multiple Sclerosis Journal - Experimental Translational and Clinical vol. 5 , ( 4 )

Middleton R, Allen-Philbey K, Schmierer K, Espasandin M, Roberts C, Nicholas R, Rodgers J, Lockhart-Jones H et al. ( 2019 ) . 175 A model for participant engagement in research: the MS register . Journal of Neurology Neurosurgery & Psychiatry . vol. 90 ,

Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al. ( 2019 ) . 192 Does socioeconomic status impact on the prescription of disease-modifying treatments in people with multiple sclerosis? . Journal of Neurology Neurosurgery & Psychiatry . vol. 90 ,

Allen-Philbey K, Silveira F, Turner B, Giovannoni G, Schmierer K ( 2019 ) . 212 Is there an ethnicity bias of access to MS services? The barts health experience revisited . Journal of Neurology Neurosurgery & Psychiatry . vol. 90 ,

Baker D, Pryce G, James LK, Schmierer K, Giovannoni G ( 2019 ) . Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis . European Journal of Neurology vol. 27 , ( 2 ) 221 - 228 .

Baker D, Jacobs BM, Gnanapavan S, Schmierer K, Giovannoni G ( 2019 ) . Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 35 , 19 - 25 .

Schmierer K, Campion T, Sinclair A, van Hecke W, Matthews PM, Wattjes MP ( 2019 ) . Towards a standard MRI protocol for multiple sclerosis across the UK . Br J Radiol20180926 - 20180926 .

De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al. ( 2019 ) . Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients (S26.008) . Neurology vol. 92 , ( 15_supplement )

Carrillo-Loza K, Reyes S, Bianchi L, Holden D, Espasandin M, Ammoscato F, Turner B, Schmierer K et al. ( 2019 ) . Real Life Evidence for CSF Neurofilaments Light Chain in Clinical Practice. (P5.2-021) . Neurology vol. 92 , ( 15_supplement )

Mateo-Casas M, Reyes S, De Trane S, Yildiz O, Turner B, Mathews J, Giovannoni G, O’toole E et al. ( 2019 ) . Severe skin reactions associated with Cladribine treatment in patients with multiple sclerosis (P4.2-022) . Neurology vol. 92 , ( 15_supplement )

Baker D, Pryce G, Herrod SS, Schmierer K ( 2019 ) . Potential mechanisms of action related to the efficacy and safety of cladribine . Multiple Sclerosis and Related Disorders vol. 30 , 176 - 186 .

Filippi M, Brück W, Chard D, Fazekas F, Geurts JJG, Enzinger C, Hametner S, Kuhlmann T et al. ( 2019 ) . Association between pathological and MRI findings in multiple sclerosis . The Lancet Neurology vol. 18 , ( 2 ) 198 - 210 .

Cores C, Reyes S, De Trane S, Giovannoni G, Schmierer K, Baker D ( 2019 ) . Are poor depleters worse off? Variation in total lymphocyte reduction following MS treatment with cladribine . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 745 - 746 .

De Trane S, Allen-Philbey K, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2019 ) . Cladribine at all stages of MS: two-year follow-up in 154 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 519 - 520 .

De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al. ( 2019 ) . Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients . NEUROLOGY . vol. 92 ,

Reyes S, Carrillo-Loza K, Mateo M, Bianchi L, Holden D, Ammoscato F, Marta M, Turner B et al. ( 2019 ) . Evidence of the utility of CSF neurofilament light chain measurements in people with MS in clinical practice . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 854 - 854 .

Marta M, Bianchi L, Lieberman D, Ciccarelli O, Collorone S, Kapoor R, Chataway J, Schmierer K et al. ( 2019 ) . Oxcarbazepine as a neuroprotective agent in MS: a phase IIa trial (PROXIMUS) . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 91 - 91 .

Allen-Philbey K, Miller J, Giovannoni G, Schmierer K, Turner B ( 2019 ) . Pharmacovigilance of urinary tract infections in Alemtuzumab cohort . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 321 - 322 .

Carrillo-Loza K, Reyes S, Bianchi L, Holden D, Espasandin M, Ammoscato F, Turner B, Schmierer K et al. ( 2019 ) . Real life Evidence for CSF Neurofilaments Light Chain in Clinical Practice . NEUROLOGY . vol. 92 ,

Schmierer K, Barts MS ( 2019 ) . Relapses, inflammation, progression: mind our life-changing language . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 6 - 6 .

de Stefano N, Achiron A, Barkhof F, Chan A, Derfuss T, Hodgkinson S, Leocani L, Montalban X et al. ( 2019 ) . The MAGNIFY-MS study: Mavenclad Tablets in Active RMS . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 469 - 470 .

Eskyte I, Manzano A, Pepper G, Pavitt S, Ford H, Bekker H, Chataway J, Schmierer K et al. ( 2018 ) . Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis . Multiple Sclerosis and Related Disorders vol. 27 , 370 - 377 .

Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2018 ) . Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies . Multiple Sclerosis and Related Disorders vol. 27 , 247 - 253 .

Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K et al. ( 2018 ) . e-Health and multiple sclerosis: An update . Mult Scler vol. 24 , ( 13 ) 1657 - 1664 .

Schmierer K, Miquel ME ( 2018 ) . Magnetic resonance imaging correlates of neuro-axonal pathology in the MS spinal cord . Brain Pathol vol. 28 , ( 5 ) 765 - 772 .

Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G ( 2018 ) . Inclusion criteria used in trials of people with progressive multiple sclerosis . Mult Scler1352458518803769 - 1352458518803769 .

de Stefano N, Achiron A, Barkhof F, Chan A, Derfuss T, Hodgkinson S, Leocani L, Montalban X et al. ( 2018 ) . THUR 174 The magnify-ms study: mavenclad® tablets in active rms . Journal of Neurology Neurosurgery & Psychiatry . vol. 89 , a23 - a23 .

BAKER D, GIOVANNONI G, PRYCE G, AMOR S, SCHMIERER K ( 2018 ) . Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis . Brain

Webb EJD, Meads D, Eskyte I, King N, Dracup N, Chataway J, Ford HL, Marti J et al. ( 2018 ) . A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis . Patient vol. 11 , ( 4 ) 391 - 402 .

Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K ( 2018 ) . Cladribine: mechanisms and mysteries in multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry vol. 89 , ( 12 )

Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al. ( 2018 ) . A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study . Multiple Sclerosis and Related Disorders vol. 24 , 123 - 128 .

Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al. ( 2018 ) . Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? . Multiple Sclerosis Journal - Experimental, Translational and Clinical vol. 4 , ( 2 ) 2055217318783767 - 2055217318783767 .

Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine . Multiple Sclerosis and Related Disorders vol. 24 , 20 - 27 .

Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K et al. ( 2018 ) . Validating the portal population of the United Kingdom Multiple Sclerosis Register . Multiple Sclerosis and Related Disorders vol. 24 , 3 - 10 .

Stavrou M, Francis L, Tshuma N, Schmierer K ( 2018 ) . Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis . BMJ Case Rep vol. 2018 ,

Jacobs BM, Giovannoni G, Schmierer K ( 2018 ) . No Evident Disease Activity-More Than a Risky Ambition? . JAMA Neurol

Ceronie B, Dubuisson N, Jacobs BM, Mao Z, Ammoscato F, Lock H, Longhurst H, Giovannoni G et al. ( 2018 ) . Cladribine for the Effective Control of Multiple Sclerosis via Memory B Cell Depletion (S52.007) . Neurology . vol. 90 ,

Ceronie B, Dubuisson N, Ammoscato F, Baker D, Giovannoni G, Schmierer K ( 2018 ) . Memory B Cells: Toward a Unified Therapeutic Target for Effective Immunotherapy in Multiple Sclerosis (P5.365) . Neurology . vol. 90 ,

Mao Z, Alvarez-Gonzalez C, Yildiz O, Allen-Philbey K, Turner B, Gnananpavan S, Marta M, Mathews J et al. ( 2018 ) . Personalised dosing of cladribine for people with multiple sclerosis (P3.400) . Neurology . vol. 90 ,

Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al. ( 2018 ) . The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis. (P2.346) . Neurology . vol. 90 ,

Cerqueira JJ, Compston DAS, Geraldes R, Rosa MM, Schmierer K, Thompson A, Tinelli M, Palace J ( 2018 ) . Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? . Journal of Neurology Neurosurgery & Psychiatry vol. 89 , ( 8 )

Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, Lock H, Longhurst HJ et al. ( 2018 ) . Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells . Journal of Neurology vol. 265 , ( 5 ) 1199 - 1209 .

Keddie S, Adams A, Kelso ARC, Turner B, Schmierer K, Gnanapavan S, Malaspina A, Giovannoni G et al. ( 2018 ) . No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation . Journal of Neurology vol. 265 , ( 5 ) 1089 - 1095 .

Schmierer K, McDowell A, Petrova N, Carassiti D, Thomas DL, Miquel ME ( 2018 ) . Quantifying multiple sclerosis pathology in post mortem spinal cord using MRI . NeuroImage vol. 182 , 251 - 258 .

Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al. ( 2018 ) . Alemtuzumab depletion failure can occur in multiple sclerosis . Immunology vol. 154 , ( 2 ) 253 - 260 .

Manzano A, Eskyte I, Pepper G, Ford HL, Bekker HL, Chataway J, Schmierer K, Meads D et al. ( 2018 ) . "We'll test your blood for an infection that might kill you" - a qualitative study describing how risks of disease modifying treatment are communicated to people with relapsing multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 943 - 944 .

De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2018 ) . Cladribine personalised dosing in people with MS (n>200) - four years experience in clinical care .

Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Elevated neurofilament light chain levels in progressive multiple sclerosis effectively reduced by cladribine treatment . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 949 - 949 .

Jacobs B, Ammoscato F, Ceronie B, Xenakis T, Baker D, Giovannoni G, Schmierer K ( 2018 ) . Explaining long-term depletion of memory B lymphocytes after cladribine treatment . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 894 - 894 .

Giovannoni G, Brex P, Walters E, Al-Izki S, Dhiraj D, Schmierer K ( 2018 ) . Glatiramer acetate slows disability progression - final 10-year results from UK Risk Sharing Scheme . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 728 - 729 .

Allen-Philbey K, Lee QM, Francis M, Giovannoni G, Schmierer K, Turner B ( 2018 ) . Real-world experience of the effectiveness, safety and tolerability of dimethyl fumarate in Barts Health MS cohort . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 276 - 277 .

Allen-Philbey K, Yildiz O, Raciborska D, Stennett A, Mathews J, Turner B, Giovannoni G, Schmierer K ( 2018 ) . Systematic multidimensional clinical point-of-care monitoring of people with multiple sclerosis using 3test . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 569 - 569 .

Allen-Philbey K, Albor C, Raciborska D, Turner B, Giovannoni G, Schmierer K ( 2017 ) . PO109 Is there an ethnicity bias of access to multiple services in the nhs? – the barts health experience . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,

Dubuisson N, Bauer A, Marta M, Gnanapavan S, Turner B, Baker D, Giovannoni G, Schmierer K et al. ( 2017 ) . PO124 Validation of an environmentally-friendly and affordable cardboard 9-hole peg test . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,

Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Gnanapavan S, Marta M, Baker D et al. ( 2017 ) . PO134 Personalised dosing of cladribine to treat multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,

Schmierer K, Herrod S, Alvarez-Gonzalez C, Giovannoni G, Baker D ( 2017 ) . PO149 A new perspective on autoimmunity after alemtuzumab . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,

Schmierer K, Marta M, Pryce G, Giovannoni G, Baker D ( 2017 ) . PO150 Memory b cells are key for immunotherapy in multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 , a52 - a52 .

Shafei R, Fourali S, Hateley S, Dubuisson N, Davidson H, Turner B, Gnanapavan S, Giovannoni G et al. ( 2017 ) . PO151 Infections in patients with multiple sclerosis on alemtuzumab – should antibiotic prophylaxis be standard? . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,

Baker D, Giovannoni G, Schmierer K ( 2017 ) . Marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment . Multiple Sclerosis and Related Disorders

Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K ( 2017 ) . Both cladribine and alemtuzumab may affect MS via B-cell depletion (vol 4, e360, 2017) . NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION vol. 4 , ( 5 )

Dubuisson N, Bauer A, Buckley M, Gilbert R, Paterson A, Marta M, Gnanapavan S, Turner B et al. ( 2017 ) . Validation of an environmentally-friendly and affordable cardboard 9-hole peg test . Multiple Sclerosis and Related Disorders vol. 17 , 172 - 176 .

Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K ( 2017 ) . Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab . JAMA Neurol vol. 74 , ( 8 ) 961 - 969 .

Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K ( 2017 ) . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis . Mult Scler1352458517726380 - 1352458517726380 .

Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Waubant E, Goldacre MJ ( 2017 ) . Psychiatric disorders in children with demyelinating diseases of the central nervous system . Multiple Sclerosis Journal vol. 24 , ( 9 ) 1243 - 1250 .

Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K ( 2017 ) . Disease modification in advanced MS: Focus on upper limb function . Multiple Sclerosis Journal vol. 23 , ( 14 ) 1956 - 1957 .

Birkl C, Carassiti D, Hussain F, Langkammer C, Enzinger C, Fazekas F, Schmierer K, Ropele S ( 2017 ) . Assessment of ferritin content in multiple sclerosis brains using temperature‐induced R*2 changes . Magnetic Resonance in Medicine vol. 79 , ( 3 ) 1609 - 1615 .

Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K ( 2017 ) . Both cladribine and alemtuzumab may effect MS via B-cell depletion . Neurology Neuroimmunology & Neuroinflammation vol. 4 , ( 4 )

BAKER D, SCHMIERER K, Herrod S, Alvarez Gonzalez C, Zalewski L, Albor C ( 2017 ) . Both cladribine and alemtuzumab may effect multiple sclerosis via B cell depletion . Neurology: Neuroimmunology and Neuroinflammation vol. 4 , ( 4 )

Carassiti D, Altmann DR, Petrova N, Pakkenberg B, Scaravilli F, Schmierer K ( 2017 ) . Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex . Neuropathology and Applied Neurobiology vol. 44 , ( 4 ) 377 - 390 .

Alvarez-Gonzalez C, Adams A, Mathews J, Turner BP, Giovannoni G, Baker D, Schmierer K ( 2017 ) . Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis . Annals of Clinical and Translational Neurology

Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K ( 2017 ) . Axonal loss in the multiple sclerosis spinal cord revisited . Brain Pathology vol. 28 , ( 3 ) 334 - 348 .

Schmierer K, Herrod S, Alvarez-Gonzalez C, Baker D ( 2017 ) . Cladribine versus Alemtuzumab: efficacy and autoimmunity in multiple sclerosis induction treatment (P6.383) . Neurology . vol. 88 ,

Campion T, Smith RJP, Altmann DR, Brito GC, Turner BP, Evanson J, George IC, Sati P et al. ( 2017 ) . FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis? . European Radiology vol. 27 , ( 10 ) 4257 - 4263 .

Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K ( 2017 ) . Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis . EBioMedicine vol. 16 , 41 - 50 .

Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D et al. ( 2017 ) . Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses . Multiple Sclerosis and Related Disorders vol. 12 , 70 - 78 .

Middleton RM, Rodgers WJ, Giovannoni G, Schmierer K, Dobson R, Allen-Philbey K, Patterson A, Akbari A et al. ( 2017 ) . A Comparison of participant supplied EDSS scores and clinically submitted data via the UK MS Register . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 153 - 154 .

Baker D, Kang AS, Gnanapavan S, Giovannoni G, Schmierer K ( 2017 ) . A central role of B cells in MS control and causing autoimmunity after alemtuzumab . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 336 - 336 .

Ceronie B, Zhifeng M, Ammoscato F, Lock H, Longhurst HJ, Giovannoni G, Baker D, Schmierer K ( 2017 ) . Cladribine controls multiple sclerosis via memory B cell depletion . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 1011 - 1012 .

Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Turner B, Gnanapavan S, Marta M, Mathews J, Giovannoni G et al. ( 2017 ) . Cladribine personalised dosing to treat multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 609 - 609 .

Afolabi D, Albor C, Altmann DR, Zalewski L, Baker D, Schmierer K ( 2017 ) . Cladribine tablets treating multiple sclerosis orally (CLARITY): an independent analysis of the quality of life data . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 423 - 423 .

Albor C, du Sautoy T, Kali Vanan N, Turner BP, Boomla K, Schmierer K ( 2017 ) . Ethnicity and prevalence of multiple sclerosis in east London . Mult Scler vol. 23 , ( 1 ) 36 - 42 .

Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Schmierer K, Giovannoni G ( 2017 ) . Identification of main inclusion criteria of chronic progressive multiple sclerosis clinical trials: a review . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 939 - 940 .

Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Waubant E, Goldacre M ( 2017 ) . Risks of psychiatric disorders in children and young adults with demyelinating diseases of the central nervous system: a national record-linkage study . NEUROLOGY . vol. 88 ,

Ford H, Manzano A, Eskyte I, Pavitt S, Pepper G, Schmierer K, Chataway J, Potrata B et al. ( 2017 ) . Understanding the treatment preferences of people with relapsing remitting multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 919 - 920 .

Stavrou M, Smith D, Shaw P, Raciborska D, Silber E, Brex P, Giovannoni G, Schmierer K et al. ( 2016 ) . REAL WORLD EXPERIENCE OF FINGOLIMOD IN MULTIPLE SCLEROSIS: THE LONDON AUDIT . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . Conference: ABN vol. 87 ,

Davis A, Turner B, Ramadhan M, Albor C, Schmierer K, Giovannoni G ( 2016 ) . THE BURDEN OF BLADDER DYSFUNCTION IN MULTIPLE SCLEROSIS: A MULTI-CENTRE AUDIT . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . Conference: ABN vol. 87 ,

Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Baker D, Gnanapavan S, Marta M, Giovannoni G et al. ( 2016 ) . TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 87 ,

Dobson R, Ramagopalan S, Topping J, Smith P, Solanky B, Schmierer K, Chard D, Giovannoni G ( 2016 ) . A Risk Score for Predicting Multiple Sclerosis . PLoS One vol. 11 , ( 11 ) Article 0164992 , e0164992 - e0164992 .

Pakpoor J, Wotton CJ, Schmierer K, Giovannoni G, Goldacre M ( 2016 ) . Gender identity disorders and multiple sclerosis risk: A national record-linkage study . MULTIPLE SCLEROSIS JOURNAL vol. 22 , ( 13 ) 1759 - 1762 .

Thomson A, Giovannoni G, Marta M, Gnanpavan S, Turner B, Baker D, Schmierer K ( 2016 ) . Importance of upper limb function in advanced multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 676 - 676 .

Rejdak K, Mitosek-Szewczyk K, Prus K, Trzciniecka O, Baker D, Schmierer K, Stelmasiak Z ( 2016 ) . Induction therapy of relapsing secondary multiple sclerosis using generic cladribine . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 593 - 594 .

Gold J, Marta MC, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al. ( 2016 ) . Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 188 - 189 .

Marta M, MacManus D, Yousry T, Miller D, Altmann DR, Meier UC, Christensen T, Maruszak H et al. ( 2016 ) . Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 188 - 188 .

Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Waubant E, Goldacre M ( 2016 ) . Risks of psychiatric disorders in children and young adults with demyelinating diseases of the central nervous system: a national record-linkage study . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 17 - 17 .

Petrova N, Carassiti D, Scaravilli F, Baker D, Schmierer K ( 2016 ) . Synaptic loss in the MS spinal cord: a key driver of disease progression? . MULTIPLE SCLEROSIS JOURNAL . Conference: ECTRIMS 2016 Committees ( UCL Institute of Neurology, London, UK ) from: 14/09/2016 to: 17/09/2016 , vol. 22 , 80 - 80 .

Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Espasandin M, Turner BP, Gnanapavan S, Marta M, Giovannoni G et al. ( 2016 ) . Treating multiple sclerosis with generic cladribine . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) vol. 22 , 604 - 605 .

Campion T, Schmierer K ( 2016 ) . Re: The effect of venous anatomy on the morphology of multiple sclerosis lesions: a susceptibility-weighted imaging study . Clinical Radiology

Giovannoni G, Marta M, Davis A, Turner B, Gnanapavan S, Schmierer K ( 2016 ) . Switching patients at high risk of PML from natalizumab to another disease-modifying therapy . Practical Neurologypractneurol-2015-001 - practneurol-2015-001 .

Pakpoor J, Wotton C, Schmierer K, Giovannoni G, Goldacre M ( 2016 ) . Gender Identity Disorders and Multiple Sclerosis Risk: A National Record Linkage Study . NEUROLOGY . vol. 86 ,

Pakpoor J, Wolton C, Schmierer K, Giovannoni G, Goldacre M ( 2016 ) . Gender Identity Disorders and Multiple Sclerosis Risk: A National Record-Linkage Study . NEUROLOGY . Conference: AAN vol. 86 ,

Pakpoor J, Wotton C, Schmierer K, Giovannoni G, Goldacre M ( 2016 ) . Gender identity Disorders and Multiple Sclerosis Risk: A National Record-Linkage Study . NEUROLOGY . vol. 86 ,

Raftopoulos R, Hickman S, Toosy A, Sharrack B, Mallik S, Paling D, Altmann D, Yiannakas M et al. ( 2016 ) . Prognostic Factors Associated with Axonal Loss after Optic Neuritis . NEUROLOGY . Conference: AAN vol. 86 ,

SCHMIERER K, Albor C, du Sautoy T, Kali Vanan N, Turner BP, Boomla K ( 2016 ) . Ethnicity and prevalence of multiple sclerosis in east London . Multiple Sclerosis Journal

Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC et al. ( 2016 ) . Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial . The Lancet Neurology vol. 15 , ( 3 ) 259 - 269 .

Davis A, Turner B, Ramadhan M, Albor C, Schmierer K, Giovannoni G ( 2016 ) . A multi-centre audit to describe the burden of bladder dysfunction in multiple sclerosis . EUROPEAN JOURNAL OF NEUROLOGY . vol. 23 , 531 - 531 .

Thomson A, Davis A, Paterson A, Giovannoni G, Schmierer K ( 2015 ) . DESIGNING AN INFORMATION RESOURCE TO EXPLAIN DIAGNOSTIC LUMBAR PUNCTURE AND PROMOTE BEST PRACTICE . Journal of Neurology Neurosurgery & Psychiatry . vol. 86 ,

Albor C, du Sautoy T, Vanan NK, Boomla K, Schmierer K ( 2015 ) . ETHNICITY AND MULTIPLE SCLEROSIS PREVALENCE IN EAST LONDON . Journal of Neurology Neurosurgery & Psychiatry . vol. 86 ,

Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D et al. ( 2015 ) . No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine . Neurology Neuroimmunology & Neuroinflammation vol. 2 , ( 6 )

Chaplin S, Schmierer K ( 2015 ) . Teriflunomide for relapsing remitting multiple sclerosis . Prescriber vol. 26 , ( 18 ) 11 - 14 .

Davis A, Dobson R, Kaninia S, Giovannoni G, Schmierer K ( 2015 ) . Atraumatic needles for lumbar puncture: why haven't neurologists changed? . Practical Neurology vol. 16 , ( 1 )

Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, Giovannoni G, Miller D et al. ( 2015 ) . Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis . Practical Neurology vol. 15 , ( 4 )

Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M ( 2015 ) . Is it time to target no evident disease activity (NEDA) in multiple sclerosis? . Multiple Sclerosis and Related Disorders vol. 4 , ( 4 ) 329 - 333 .

Pakpoor J, Disanto G, Altmann D, Pavitt S, Turner B, Marta M, Juliusson G, Baker D et al. ( 2015 ) . Cancer Risk is Not Increased in People with Relapsing Multiple Sclerosis Taking Cladribine (P7.011) . Neurology vol. 84 , ( 14_supplement )

Campion T, Smith P, Turner B, Altmann D, Sati P, Evanson J, George I, Miquel M et al. ( 2015 ) . FLAIR* for the non-invasive histological diagnosis of multiple sclerosis (S29.003) . Neurology vol. 84 , ( 14_supplement )

Raftopoulos R, Chen C-L, Hickman S, Toosy A, Wheeler-Kingshott C, Altmann D, Mallik S, Paling D et al. ( 2015 ) . Swelling of the Outer Retinal Layers in Acute Optic Neuritis (P4.042) . Neurology vol. 84 , ( 14_supplement )

Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Goldacre M ( 2015 ) . Testicular Hypofunction and Multiple Sclerosis Risk: A Record-Linkage Study (P1.101) . Neurology vol. 84 , ( 14_supplement )

Carassiti D, Pakkenberg B, Scaravilli F, Schmierer K ( 2015 ) . Cortical atrophy predicts neuronal loss in MS: a post mortem study using unbiased sampling . MULTIPLE SCLEROSIS JOURNAL . vol. 21 , 423 - 424 .

Thomson A, Davis A, Paterson A, Giovannoni G, Schmierer K ( 2015 ) . Designing an information resource to explain diagnostic lumbar puncture and promote best practice . EUROPEAN JOURNAL OF NEUROLOGY . vol. 22 , 491 - 492 .

Giovannoni G, Brex P, Sumra M, Walters E, Schmierer K ( 2015 ) . Glatiramer acetate slows disability progression - results from a 6-year analysis of the UK Risk Sharing Scheme . MULTIPLE SCLEROSIS JOURNAL . vol. 21 , 800 - 801 .

Raftopoulos R, Hickman S, Toosy A, Sharrack B, Mallik S, Altmann D, Malladi P, Koltzenburg M et al. ( 2015 ) . Neuroprotection with phenytoin in acute optic neuritis: results of a phase II randomised controlled trial . EUROPEAN JOURNAL OF NEUROLOGY . vol. 22 , 48 - 48 .

Schmierer K ( 2015 ) . New Perspectives on Inflammatory CNS Disease Therapies . MULTIPLE SCLEROSIS JOURNAL . vol. 21 , 802 - 803 .

Schmierer K ( 2015 ) . Pathological and MRI markers of deterioration . MULTIPLE SCLEROSIS JOURNAL vol. 21 , ( 6 ) 799 - 800 .

Raftopoulos R, Rangarajan A, Chen C-L, Hickman S, Toosy A, Wheeler-Kingshott CA, Altmann D, Malik S et al. ( 2015 ) . Sodium channel blockade with phenytoin has a neuroprotective effect on the ganglion cell complex after acute optic neuritis . MULTIPLE SCLEROSIS JOURNAL . vol. 21 , 273 - 274 .

Raciborska D, Turner B, Schmierer K ( 2015 ) . Switching MS patients from natalizumab to fingolimod therapy: comparison of short and prolonged washout periods . EUROPEAN JOURNAL OF NEUROLOGY . vol. 22 , 350 - 350 .

Giovannoni G, Baker D, Schmierer K ( 2015 ) . The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? . Multiple Sclerosis and Related Disorders vol. 4 , ( 1 ) 3 - 5 .

Chaplin S, Schmierer K ( 2014 ) . Dimethyl fumarate for relapsingremitting multiple sclerosis . Prescriber vol. 25 , ( 23-24 ) 37 - 39 .

Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Goldacre MJ ( 2014 ) . Testicular hypofunction and multiple sclerosis: Cause or consequence? Reply . Ann Neurol vol. 76 , ( 5 ) 765 - 766 .

Pakpoor J, Goldacre R, Schmierer K, Giovannoni G, Goldacre MJ ( 2014 ) . Testicular hypofunction and multiple sclerosis risk: a record-linkage study . Ann Neurol vol. 76 , ( 4 ) 625 - 628 .

Giovannoni G, Baker D, Schmierer K ( 2014 ) . Simvastatin in patients with progressive multiple sclerosis . Lancet vol. 384 , ( 9947 )

Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner B, Calado-Marta M, Juliusson G, Baker D et al. ( 2014 ) . CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE . Journal of Neurology Neurosurgery & Psychiatry . vol. 85 , e4 - e4 .

Schmierer K, Marta M, Turner, Giovannoni G ( 2014 ) . THE USE OF MAGNETIC RESONANCE IMAGING (MRI) IN THE MANAGEMENT OF MULTIPLE SCLEROSIS IN THE UK . Journal of Neurology Neurosurgery & Psychiatry . vol. 85 , e4 - e4 .

Dobson R, Topping J, Chard D, Schmierer K, Smith P, Ramagopalan S, Giovannoni G ( 2014 ) . A Multivariate Risk Calculator for Multiple Sclerosis and Study of an Endophenotype in Siblings of People with Multiple Sclerosis (S34.002) . Neurology vol. 82 , ( 10_supplement )

Carassiti D, Al Zawawi S, Schmierer K ( 2014 ) . Does Axonal Degeneration Depend on Demyelination in Chronic Multiple Sclerosis? (P1.191) . Neurology vol. 82 , ( 10_supplement )

Raftopoulos R, Hickman S, Toosy A, Wheeler-Kingshott C, Altmann D, Mallik S, Paling D, Yiannakas M et al. ( 2014 ) . OCT, Visual Function and MRI Measures in Acute Optic Neuritis: Baseline Data from a Clinical Trial (P2.255) . Neurology vol. 82 , ( 10_supplement )

Carassiti D, Papachatzaki M, Scaravilli F, Schmierer K ( 2014 ) . The Global Neocortical Loss Of Neurons In Multiple Sclerosis (P1.190) . Neurology vol. 82 , ( 10_supplement )

Gnanapavan S, Jaunmuktane Z, Baruteau KP, Gnanasambandam S, Schmierer K ( 2014 ) . A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome . BMC Neurol vol. 14 ,

Wallner-Blazek M, Rovira A, Filippi M, Rocca MA, Miller DH, Schmierer K, Frederiksen J, Gass A et al. ( 2014 ) . Erratum to: Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis . J Neurol vol. 261 , ( 4 ) 848 - 849 .

Davis A, Dobson R, Kaninia S, Espasandin M, Berg A, Giovannoni G, Schmierer K ( 2014 ) . Change practice now! Using atraumatic needles to prevent post lumbar puncture headache . Eur J Neurol vol. 21 , ( 2 ) 305 - 311 .

Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G ( 2014 ) . Assessing treatment response to interferon-β: is there a role for MRI? . Neurology vol. 82 , ( 3 ) 248 - 254 .

Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G ( 2014 ) . Assessing treatment response to interferon-β Is there a role for MRI? . NEUROLOGY vol. 82 , ( 3 ) 248 - 254 .

Campion T, Smith P, Altmann DR, Turner BP, Evanson J, George IC, Sati P, Reich DS et al. ( 2014 ) . FLAIR* for the non-invasive histological diagnosis of MS . MULTIPLE SCLEROSIS JOURNAL . vol. 20 , 289 - 290 .

Schmierer K ( 2014 ) . Repurposing drugs for disease modification in multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 20 , 35 - 36 .

Carassiti D, Papachatzaki M, Scaravilli F, Pakkenberg B, Schmierer K ( 2014 ) . The loss of neurons over the whole MS neocortex . MULTIPLE SCLEROSIS JOURNAL . vol. 20 , 59 - 59 .

Carassiti D, Petrova N, Al-Zawawi S, Scaravilli F, Schmierer K ( 2014 ) . The relationship between axonal loss and demyelination in the MS spinal cord . MULTIPLE SCLEROSIS JOURNAL . vol. 20 , 366 - 366 .

Papachatzaki MM, Ali N, Arshad Q, Cader S, Peppas I, Everett C, Bronstein AM, Schmierer K ( 2013 ) . Progressive ataxia with oculo-palatal tremor and optic atrophy . J Neurol vol. 260 , ( 11 ) 2903 - 2905 .

Albor C, Richards O, Ramagopalan S, Boomla K, Schmierer K ( 2013 ) . Using routine point-of-care data for research: the East london multiple sclerosis cohort . J Neurol Neurosurg Psychiatry vol. 84 , ( 11 )

Altmann DR, Button T, Schmierer K, Hunter K, Tozer DJ, Wheeler-Kingshott CA, Coles A, Miller DH ( 2013 ) . Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 3 , ( 2 ) 237 - 243 .

Vecchio D, Albor C, Richards OJ, Turner BP, Giovannoni G, Schmierer K ( 2013 ) . Do disease modifying treatments improve outcome? First results from the London MS Database . Journal of the Neurological Sciences vol. 333 ,

Wallner-Blazek M, Rovira A, Fillipp M, Rocca MA, Miller DH, Schmierer K, Frederiksen J, Gass A et al. ( 2013 ) . Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis . J Neurol vol. 260 , ( 8 ) 2016 - 2022 .

Yiannakas MC, Tozer DJ, Schmierer K, Chard DT, Anderson VM, Altmann DR, Miller DH, Wheeler-Kingshott CAM ( 2013 ) . ADvanced IMage Algebra (ADIMA): a novel method for depicting multiple sclerosis lesion heterogeneity, as demonstrated by quantitative MRI . Mult Scler vol. 19 , ( 6 ) 732 - 741 .

Valdueza JM, Doepp F, Schreiber SJ, van Oosten BW, Schmierer K, Paul F, Wattjes MP ( 2013 ) . What went wrong? The flawed concept of cerebrospinal venous insufficiency . J Cereb Blood Flow Metab vol. 33 , ( 5 ) 657 - 668 .

Schmierer K, Papachatzaki MM ( 2013 ) . A single lesion—And yet MS? . Multiple Sclerosis and Related Disorders vol. 2 , ( 3 ) 154 - 155 .

Carassiti D, Papachatzaki M, Scaravilli F, Schmierer K ( 2013 ) . Accurate estimates of whole brain neuronal loss in multiple sclerosis using unbiased quantitative histology . MULTIPLE SCLEROSIS JOURNAL . vol. 19 , 161 - 161 .

Raftopoulos RE, Hickman S, Toosy A, Wheeler-Kingshott CA, Altmann D, Malik S, Paling D, Yiannakas M et al. ( 2013 ) . Optical coherence tomography (OCT), visual function and MRI measures in acute optic neuritis: baseline data from a clinical trial . MULTIPLE SCLEROSIS JOURNAL . vol. 19 , 8 - 9 .

Papachatzaki MM, Carassiti D, McDowell A, Schmierer K ( 2013 ) . Stereological estimates of neuronal loss in the primary motor cortex of multiple sclerosis patients . MULTIPLE SCLEROSIS JOURNAL . vol. 19 , 571 - 572 .

Arnold DL, Dalton CM, Schmierer K, Pike GB, Miller DH ( 2012 ) . Imaging of Demyelination and Remyelination in Multiple Sclerosis . Myelin Repair and Neuroprotection in Multiple Sclerosis , Springer Nature

Filippi M, Rocca MA, Barkhof F, Brück W, Chen JT, Comi G, DeLuca G, De Stefano N et al. ( 2012 ) . Association between pathological and MRI findings in multiple sclerosis . The Lancet Neurology vol. 11 , ( 4 ) 349 - 360 .

Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K et al. ( 2012 ) . Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study . Mult Scler vol. 18 , ( 3 ) 314 - 321 .

Chaplin S, Schmierer K, Farrell R ( 2012 ) . Fingolimod: new oral treatment for relapsing‐remitting MS . Prescriber vol. 23 , ( 3 ) 20 - 25 .

Symms M, Jäger HR, Schmierer K, Yousry TA ( 2012 ) . A Review of Structural Magnetic Resonance Neuroimaging . Neuroscience for Neurologists , World Scientific Publishing

Papachatzaki MM, Ali N, Peppas Y, Cader S, Everett C, Schmierer K ( 2012 ) . A NEW PHENOTYPE OF PAPT: PROGRESSIVE ATAXIA, PALATAL TREMOR AND OPTIC ATROPHY . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . vol. 83 ,

Raftopoulos RE, Hickman S, Toosy A, Wheeler-Kingshott CA, Altmann D, Schmierer K, Sharrack B, Sheridan R et al. ( 2012 ) . A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis . MULTIPLE SCLEROSIS JOURNAL . vol. 18 , 442 - 443 .

Davis A, Dobson R, Espasandin M, Giovannoni G, Schmierer K ( 2012 ) . Cerebrospinal fluid biomarkers as outcome measures in clinical trials of MS: The significance of post lumbar puncture headaches . MULTIPLE SCLEROSIS JOURNAL . vol. 18 , 237 - 238 .

Dobson R, Meier UC, Schmierer K, Giovannoni G ( 2012 ) . DO SIBLINGS OF PEOPLE WITH MULTIPLE SCLEROSIS (MS) HAVE MARKERS OF MS RISK? . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . vol. 83 ,

Mougin OE, Mistry N, Papachatzaki MM, Gowland P, Evangelou N, Schmierer K ( 2012 ) . MULTI-MODAL MRI AT 7T TO DETECT AND QUANTIFY MULTIPLE SCLEROSIS CORTICAL GREY MATTER PATHOLOGY . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . vol. 83 ,

SCHMIERER K ( 2012 ) . Magnetic resonance imaging in multiple sclerosis . Multiple Sclerosis (Visual Guide for Clinicians) , Editors: Dobson, R, Giovannoni, G , Atlas Medical Publishing

Davis A, Espasandin MD, Schmierer K ( 2012 ) . OVER 100 YEARS OF POST LUMBAR PUNCTURE HEADACHE, AND COUNTING . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . vol. 83 ,

Altmann DR, Button T, Schmierer K, Hunter K, Tozer D, Wheeler-Kingshott C, Coles A, Miller DH ( 2012 ) . Sample sizes for lesion magnetisation transfer ratio outcome measures in remyelination trials for multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 18 , 470 - 470 .

Petzold A, Tozer DJ, Schmierer K ( 2011 ) . Axonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter . Exp Neurol vol. 232 , ( 2 ) 234 - 239 .

Schmierer K, Tozer DJ, Petzold A ( 2011 ) . Axonal Damage in the Making: Neurofilament Phosphorylation and Magnetization Transfer in Multiple Sclerosis Non-Lesional White Matter . NEUROLOGY . vol. 76 , A358 - A358 .

MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, Polman CH, Schmierer K et al. ( 2011 ) . BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis . J Neurol vol. 258 , ( 3 ) 449 - 456 .

Connolly F, Paul F, Valdueza JM, Julika F, Schmierer K, Stephan SJ ( 2011 ) . Patients with Multiple Sclerosis Do Not Suffer from Cerebro-Cervical Venous Congestion . NEUROLOGY . vol. 76 , A171 - A171 .

Ugradar SY, Parkes H, So PW, Miller DH, Jackson S, Scaravilli F, Schmierer K ( 2011 ) . Quantifying Remyelination in Multiple Sclerosis Using High Field (9.4T) Magnetic Resonance Imaging . NEUROLOGY . vol. 76 , A172 - A172 .

Dobson R, Meier UC, Schmierer K, Giovannoni G ( 2011 ) . Do siblings have markers of multiple sclerosis risk? . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S86 - S86 .

Schmierer K, Tozer D, Petzold A ( 2011 ) . In multiple sclerosis' protein phosphorylation competes with the free proton binding capacity in post-mortem brain tissue . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S503 - S503 .

Schmierer K ( 2010 ) . Imaging of human inflammatory neurodegenerative disorders . IMMUNOLOGY . vol. 131 , 5 - 5 .

Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ ( 2010 ) . Reply . Ann Neurol vol. 68 , ( 6 )

Schmierer K, Thavarajah JR, An SF, Brandner S, Miller DH, Tozer DJ ( 2010 ) . Effects of formalin fixation on magnetic resonance indices in multiple sclerosis cortical gray matter . J Magn Reson Imaging vol. 32 , ( 5 ) 1054 - 1060 .

Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ ( 2010 ) . Multiple Sclerosis Appears To Be Associated with Cerebral Venous Abnormalities Reply . ANN NEUROL vol. 68 , ( 4 ) 561 - 562 .

Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ ( 2010 ) . No cerebrocervical venous congestion in patients with multiple sclerosis . Ann Neurol vol. 68 , ( 2 ) 173 - 183 .

Schmierer K, Parkes HG, So P-W, An SF, Brandner S, Ordidge RJ, Yousry TA, Miller DH ( 2010 ) . High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis . Brain vol. 133 , ( Pt 3 ) 858 - 867 .

Schmierer K ( 2009 ) . HIGH FIELD MRI REVEALS MULTIPLE SCLEROSIS CORTICAL GREY MATTER LESIONS AND ALLOWS QUANTITATIVE ASSESSMENT OF NEURONS AND AXONS . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . vol. 80 ,

Parkes H, So PW, Brandner S, An S, Miller D, Yousry T, Schmierer K ( 2009 ) . Quantifying cortical pathology in multiple sclerosis using high-field MRI . MULTIPLE SCLEROSIS . vol. 15 , S91 - S91 .

Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, Khaleeli Z, Schmierer K et al. ( 2009 ) . Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI . NEUROLOGY vol. 73 , ( 1 ) 32 - 38 .

Fisniku LK, Altmann DR, Cercignani M, Tozer DJ, Chard DT, Jackson JS, Miszkiel KA, Schmierer K et al. ( 2009 ) . Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis . Mult Scler vol. 15 , ( 6 ) 668 - 677 .

Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O et al. ( 2009 ) . GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study . Neurology vol. 72 , ( 9 ) 806 - 812 .

Schmierer K, Parkes HG, So P-W ( 2009 ) . Direct visualization of remyelination in multiple sclerosis using T2-weighted high-field MRI . Neurology vol. 72 , ( 5 )

Schmierer K ( 2008 ) . Commentary on: "Dirty-appearing white matter in multiple sclerosis . J NEUROL vol. 255 , ( 11 ) 1812 - 1812 .

Schmierer K ( 2008 ) . Commentary on: "Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss", by G. R. W. Moore, et al. in J Neurol (2008) 255: DOI 10.1007/s00415-008-0002-z . J Neurol vol. 255 , ( 11 )

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K et al. ( 2008 ) . Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study . Lancet vol. 372 , ( 9648 ) 1463 - 1472 .

Petzold A, Gveric D, Groves M, Schmierer K, Grant D, Chapman M, Keir G, Cuzner L et al. ( 2008 ) . Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology . Exp Neurol vol. 213 , ( 2 ) 326 - 335 .

Parkes H, Shorter S, So PW, Baker D, Pryce G, Giovannoni G, Schmierer K ( 2008 ) . High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis . MULTIPLE SCLEROSIS . vol. 14 , S86 - S87 .

Schmierer K, Parkes H, So PW, An SF, Brandner S, Miller DH, Yousry TA ( 2008 ) . Magnetization transfer ratio: a predictor of neuronal loss in multiple sclerosis cortical gray matter? . MULTIPLE SCLEROSIS . vol. 14 , S219 - S220 .

Schmierer K, Thavarajah JR, Parkes H, Miller DH, Tozer D ( 2008 ) . Multiple sclerosis cortical grey matter changes following fixation detected by multimodal magnetic resonance imaging . MULTIPLE SCLEROSIS . vol. 14 , S220 - S220 .

MacManus DG, Miller D, Kappos L, Gold R, Havrdova E, Limmroth V, Polman C, Schmierer K et al. ( 2008 ) . The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions . MULTIPLE SCLEROSIS . vol. 14 , S163 - S163 .

Kappos L, Miller D, MacManus D, Gold R, Havrdova E, Limmroth V, Polman C, Schmierer K et al. ( 2008 ) . The efficacy of BG00012 in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2B study . NEUROLOGY . vol. 70 , A83 - A83 .

Schmierer K, Wheeler-Kingshott CAM, Tozer DJ, Boulby PA, Parkes HG, Yousry TA, Scaravilli F, Barker GJ et al. ( 2008 ) . Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation . Magn Reson Med vol. 59 , ( 2 ) 268 - 277 .

Tofts PS, Jackson JS, Tozer DJ, Cercignani M, Keir G, MacManus DG, Ridgway GR, Ridha BH et al. ( 2008 ) . Imaging cadavers: cold FLAIR and noninvasive brain thermometry using CSF diffusion . Magn Reson Med vol. 59 , ( 1 ) 190 - 195 .

Schmierer K, Meara SJP, Miller DH, Barker GJ, Cercignani M ( 2007 ) . 3D inversion recovery fast spin echo for lesion detection in post mortem multiple sclerosis brain . MULTIPLE SCLEROSIS . vol. 13 , S77 - S77 .

Parkes HG, So PW, Miller DH, Brandner S, Yousry TA, Schmierer K ( 2007 ) . High field (9.4T) magnetic resonance reveals cortical lesions in multiple sclerosis brain . MULTIPLE SCLEROSIS . vol. 13 , S72 - S73 .

Parkes HG, Denham M, Schmierer K ( 2007 ) . High-resolution 1H NMR spectroscopy of multiple sclerosis brain . MULTIPLE SCLEROSIS . vol. 13 , S251 - S252 .

Schmierer K, Tozer DJ, Scaravilli F, Altmann DR, Barker GJ, Tofts PS, Miller DH ( 2007 ) . Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain . J Magn Reson Imaging vol. 26 , ( 1 ) 41 - 51 .

Schmierer K, Wheeler-Kingshott CAM, Boulby PA, Scaravilli F, Altmann DR, Barker GJ, Tofts PS, Miller DH ( 2007 ) . Diffusion tensor imaging of post mortem multiple sclerosis brain . Neuroimage vol. 35 , ( 2 ) 467 - 477 .

Kappos L, Gold R, Miller D, MacManus DG, Havrdova E, Limmroth V, Polman C, Schmierer K et al. ( 2007 ) . Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis . NEUROLOGY . vol. 68 , A276 - A277 .

Schmierer K, Miller DH ( 2006 ) . Making sense of magnetic resonance measures in multiple sclerosis: The post mortem evidence . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . vol. 77 , 1389 - 1389 .

Bellmann-Strobl J, Aktas O, Würfel J, Schmierer K, Paul F, Zschenderlein R, Villringer A, Zipp F ( 2006 ) . Primary progressive multiple sclerosis: evidence for uncoupling disease progression and inflammation . Aktuelle Neurologie vol. 33 , ( S 1 )

Kappos L, Miller DH, MacManus DG, Gold R, Havrdova E, Limmroth V, Polman CH, Schmierer K et al. ( 2006 ) . BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis . MULTIPLE SCLEROSIS . vol. 12 , S85 - S85 .

Schmierer K, Parkes HG, So PW, Miller DH, Yousry TA ( 2006 ) . High field-high yield: detecting multiple sclerosis white matter lesions at 9.4 Tesla . MULTIPLE SCLEROSIS . vol. 12 , S45 - S45 .

Kappos L, Miller DH, MacManus DG, Gold R, Havrdova E, Limmroth V, Polrnan C, Schmierer K et al. ( 2006 ) . Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study . JOURNAL OF NEUROLOGY . vol. 253 , 27 - 27 .

Schmierer K, Tozer DJ, Boulby PA, Wheeler-Kingshott CAM, Parkes HG, Yousry TA, Tofts PS, Miller DH ( 2005 ) . Changes of quantitative magnetic resonance indices following fixation in post-mortem MS brain . MULTIPLE SCLEROSIS . vol. 11 , S141 - S141 .

Schmierer K, Tozer DJ, Scaravilli F, Tofts PS, Miller DH ( 2005 ) . Short T2 relaxation: a potential marker of myelin in post-mortem multiple sclerosis brain . MULTIPLE SCLEROSIS . vol. 11 , S141 - S141 .

Cercignani M, Symms MR, Schmierer K, Boulby PA, Tozer DJ, Ron M, Tofts PS, Barker GJ ( 2005 ) . Three-dimensional quantitative magnetisation transfer imaging of the human brain . Neuroimage vol. 27 , ( 2 ) 436 - 441 .

Lim ET, Schmierer K, Grant D, Keir G, Thompson EJ, Miller DH, Giovannoni G ( 2005 ) . A comparison of the immunology and histopathology in post mortem multiple sclerosis brain . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . vol. 76 , 615 - 616 .

Symms M, Jäger HR, Schmierer K, Yousry TA ( 2004 ) . A review of structural magnetic resonance neuroimaging . J Neurol Neurosurg Psychiatry vol. 75 , ( 9 ) 1235 - 1244 .

Schmierer K, Scaravilli E, Tozer DJ, Tofts PS, Miller DH ( 2004 ) . Magnetisation transfer as a tool to monitor multiple sclerosis: postmortem evidence . MULTIPLE SCLEROSIS . vol. 10 , S229 - S229 .

Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH ( 2004 ) . Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain . Ann Neurol vol. 56 , ( 3 ) 407 - 415 .

Schmierer K, Scaravilli E, Boulby P, Wheeler-Kingshott CAM, Miller DH ( 2004 ) . Pathological correlates of diffusion tenser imaging (DTI) in post-mortem MS brain . MULTIPLE SCLEROSIS . vol. 10 , S229 - S229 .

Schmierer K ( 2004 ) . Pathological substrates of quantitative MRI in post mortem multiple sclerosis brain . MULTIPLE SCLEROSIS . vol. 10 , S104 - S105 .

Goodman A, Bar-Or A, Miller A, Miller D, Panzara M, Rossman H, Schmierer K, Toal M ( 2004 ) . GLANCE: A double-blind, randomised, placebo-controlled, parallel-group safety study of natalizumab (Antegren) in combination with glatiramer acetate (Copaxone) in subjects with relapsing-remitting multiple sclerosis . JOURNAL OF NEUROLOGY . vol. 251 , 176 - 177 .

Schmierer K, Scaravilli E, Altmann DA, Barker GJ, Miller DH ( 2004 ) . Magnetisation transfer ratio: a robust measure of myelin content in post-mortem multiple sclerosis brain . JOURNAL OF NEUROLOGY . vol. 251 , 24 - 24 .

Kuhle J, Hardmeier M, Hooghe MD, Schmierer K, Polman C, Achiti I, Kappos L, EUSPMS Longterm Follow-up Study Gr ( 2004 ) . 8 year follow-up of the European study of Interferon beta-1b (EUSPMS) in secondary progressive MS . NEUROLOGY vol. 62 , ( 7 ) A489 - A490 .

Schmierer K, Altmann DR, Kassim N, Kitzler H, Kerskens CM, Doege CA, Aktas O, Lünemann JD et al. ( 2004 ) . Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study . Mult Scler vol. 10 , ( 2 ) 182 - 187 .

Schmierer K, Scaravilli F, Barker GJ, Gordon R, MacManus DG, Miller DH ( 2003 ) . Stereotactic co-registration of magnetic resonance imaging and histopathology in post-mortem multiple sclerosis brain . Neuropathol Appl Neurobiol vol. 29 , ( 6 ) 596 - 601 .

Mottershead JP, Schmierer K, Clemence M, Thornton JS, Scaravilli F, Barker GJ, Tofts PS, Newcombe J et al. ( 2003 ) . High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord . J Neurol vol. 250 , ( 11 ) 1293 - 1301 .

Grosse P, Schulz J, Schmierer K ( 2003 ) . Diagnostic pitfalls in eosinophilic cryptococcal meningoencephalitis . Lancet Neurol vol. 2 , ( 8 )

Schreiber SJ, Doepp F, Bender A, Schmierer K, Valdueza JM ( 2003 ) . Diffuse cerebral angiomatosis . Neurology vol. 60 , ( 7 ) 1216 - 1218 .

Dobson-Stone C, Danek A, Rampoldi L, Hardie RJ, Chalmers RM, Wood NW, Bohlega S, Dotti MT et al. ( 2002 ) . Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis . EUR J HUM GENET vol. 10 , ( 11 ) 773 - + .

Dobson-Stone C, Danek A, Rampoldi L, Hardie RJ, Chalmers RM, Wood NW, Bohlega S, Dotti MT et al. ( 2002 ) . Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis . Eur J Hum Genet vol. 10 , ( 11 ) 773 - 781 .

Schmierer K, Irlbacher K, Grosse P, Röricht S, Meyer B-U ( 2002 ) . Correlates of disability in multiple sclerosis detected by transcranial magnetic stimulation . Neurology vol. 59 , ( 8 ) 1218 - 1224 .

Schmierer K, Grosse P, De Camilli P, Solimena M, Floyd S, Zschenderlein R ( 2002 ) . Paraneoplastic stiff-person syndrome: no tumor progression over 5 years . Neurology vol. 58 , ( 1 )

Schmierer K ( 2002 ) . [Medical history and politics: careers of Fritz Lejeune during the Weimar Republic and national socialism] . Abh Gesch Med Naturwiss ( 96 ) 1 - 292 .

Schmierer K, Niehaus L, Röricht S, Meyer BU ( 2000 ) . Conduction deficits of callosal fibres in early multiple sclerosis . J Neurol Neurosurg Psychiatry vol. 68 , ( 5 ) 633 - 638 .

Wendling U, Aktas O, Schmierer K, Zschenderlein R, Zipp F ( 2000 ) . Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells--implications for multiple sclerosis . J Neuroimmunol vol. 103 , ( 1 ) 69 - 75 .

Meyer BU, Röricht S, Schmierer K, Irlbacher K, Meierkord H, Niehaus L, Grosse P ( 1999 ) . First diagnostic applications of transcallosal inhibition in diseases affecting callosal neurones (multiple sclerosis, hydrocephalus, Huntington's disease) . Electroencephalogr Clin Neurophysiol Suppl . vol. 51 , 233 - 242 .

Kappos L, Polman C, Pozzilli C, Thompson A, Dahlke F, Knight R, Hern J, Coleman R et al. ( 1998 ) . Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis . LANCET vol. 352 , ( 9139 ) 1491 - 1497 .

Schmierer K, Valdueza JM, Bender A, DeCamilli P, David C, Solimena M, Zschenderlein R ( 1998 ) . Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression . Neurology vol. 51 , ( 1 ) 250 - 252 .

Schmierer K, Roricht S, Niehaus L, Meyer BU ( 1998 ) . Impaired transcallosal inhibition: an early indicator of central conduction deficits in multiple sclerosis . 9TH EUROPEAN CONGRESS OF CLINICAL NEUROPHYSIOLOGY . Editors: Stalberg, EV, DeWeerd, AW, Zidar, J , 119 - 123 .

Meyer BU, Niehaus L, Petrow E, Schmierer K, Roricht S, Kuhn A, Irlbacher K ( 1998 ) . Inhibitory effects of transcranial magnetic motor cortex stimulation in man . 9TH EUROPEAN CONGRESS OF CLINICAL NEUROPHYSIOLOGY . Editors: Stalberg, EV, DeWeerd, AW, Zidar, J , 83 - 88 .

Valdueza JM, Schmierer K, Mehraein S, Einhäupl KM ( 1996 ) . Assessment of normal flow velocity in basal cerebral veins. A transcranial doppler ultrasound study . Stroke vol. 27 , ( 7 ) 1221 - 1225 .